Skip to main content
Clinical Trials/NCT06025903
NCT06025903
Recruiting
Not Applicable

Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis

IRCCS San Raffaele2 sites in 1 country140 target enrollmentSeptember 20, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
IRCCS San Raffaele
Enrollment
140
Locations
2
Primary Endpoint
sequencing of mitochondrial DNA
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this project is to study genetic determinants of mitochondrial impairment in primary progressive multiple sclerosis. Specific aims are: 1) identify mitochondrial-related pathways, inherited and somatic mitochondrial DNA mutations associated to primary progressive multiple sclerosis, 2) functionally assess the identified genetic alterations.

Detailed Description

Multiple Sclerosis is a major cause of neurological disability, with a high socio-economic impact that increases as disability progresses. Effective treatment of primary progressive multiple sclerosis is still an unmet need and the underlying neurodegenerative processes have to be fully investigated. The purpose of this project is to study genetic determinants of mitochondrial impairment in primary progressive multiple sclerosis. Altered mitochondrial pathways will be investigate, as well as inherited and tissue-specific somatic mitochondrial variations associated with primary progressive multiple sclerosis.

Registry
clinicaltrials.gov
Start Date
September 20, 2021
End Date
May 30, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Melissa Sorosina

Principal Investigator

IRCCS San Raffaele

Eligibility Criteria

Inclusion Criteria

  • Patients affected by primary progressive or relapsing remitting multiple sclerosis
  • Patient able to provide informed consent

Exclusion Criteria

  • Individuals with \< 18 years
  • Patients not affected by primary progressive or relapsing remitting multiple sclerosis

Outcomes

Primary Outcomes

sequencing of mitochondrial DNA

Time Frame: 3 years

the mitochondrial DNA collected from blood and cerebrospinal fluid will be sequenced and analysed, comparing the frequency of variants between the two disease courses

Study Sites (2)

Loading locations...

Similar Trials